RxDoctor Payments Data

Mary Louise Tatum, NP

Psychiatric/Mental Health · Cleveland, OHNPI 1346888450

Payments from drug & device makers

$3,309in general payments, 2019–2025

Across 31 payments — averaging $106.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Otsuka America Pharmaceutical, Inc.$352
  • Alkermes, Inc.$348
  • Vanda Pharmaceuticals Inc.$250
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$125
  • Axsome Therapeutics, Inc.$117
  • plus $101 from 2 others

What the payments were for

  • Food & beverage$3,309100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,309 in reported general payments places this provider in the 80th percentile of 1,808 psychiatric/mental health providers in Ohio.

See all psychiatric/mental health providers in Ohio

Medicare billing

Part B allowed, 2024
$7,103
Medicare patients
36
Services billed
72

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl37$52,789
RexultiBrexpiprazole11$15,926
Ramelteon16$4,755
Aripiprazole55$2,727
Bupropion XlBupropion Hcl91$2,162
Duloxetine Hcl57$2,006
Divalproex Sodium16$1,958
Buspirone Hcl80$1,868
Divalproex Sodium ErDivalproex Sodium15$1,642
Venlafaxine Hcl ErVenlafaxine Hcl50$1,388
Risperidone58$1,383
Bupropion Hcl SrBupropion Hcl32$1,312
Sertraline Hcl61$972
Quetiapine Fumarate46$852
Prazosin Hcl30$823

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$70$52,78937 claims
Otsuka America Pharmaceutical, Inc.Rexulti$352$15,92611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,808 psychiatric/mental health providers in Ohio.

Other psychiatric/mental health in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →